NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT01005472 2020-08-03
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT02400385 2017-02-01
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
Phase 2 Withdrawn
NCT00577382 2016-12-08
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00631618 2014-02-25
Clinical Trial of Sutent to Treat Metastatic Melanoma
California Pacific Medical Center Research Institute
Phase 2 Completed
NCT01216657 2013-06-04
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
Krankenhaus Nordwest
Phase 2 Terminated
NCT00496223 2011-02-23
A Phase I/II Study of Sunitinib and Dacarbazine
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00304200 2009-02-05
Temodar and Sutent as Therapy for Melanoma
Northern California Melanoma Center
Phase 1/2 Terminated